Open label study to evaluate the effect, safety and tolerability of 250 µg (8 MIU) interferon beta 1b (Betaferon) given subcutaneously every other day (for 24 weeks) in patients of Chinese origin with multiple sclerosis

Trial Profile

Open label study to evaluate the effect, safety and tolerability of 250 µg (8 MIU) interferon beta 1b (Betaferon) given subcutaneously every other day (for 24 weeks) in patients of Chinese origin with multiple sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 01 Dec 2009 The results of this trial supported the Chinese State FDA's approval of interferon beta-1b for patients with relapsing-remitting multiple sclerosis, according to a Bayer media release.
    • 12 May 2009 Actual patient number changed from 37 to 39 as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Actual patient number (37) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top